HLVX vs. ANNX, TRML, CYRX, ACB, KRRO, CRVS, PRME, MNPR, ATYR, and TRVI
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Annexon (ANNX), Tourmaline Bio (TRML), Cryoport (CYRX), Aurora Cannabis (ACB), Korro Bio (KRRO), Corvus Pharmaceuticals (CRVS), Prime Medicine (PRME), Monopar Therapeutics (MNPR), Atyr PHARMA (ATYR), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.
HilleVax vs.
Annexon (NASDAQ:ANNX) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
Annexon has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
In the previous week, Annexon had 16 more articles in the media than HilleVax. MarketBeat recorded 16 mentions for Annexon and 0 mentions for HilleVax. Annexon's average media sentiment score of 0.42 beat HilleVax's score of 0.00 indicating that Annexon is being referred to more favorably in the media.
Annexon's return on equity of -38.99% beat HilleVax's return on equity.
86.4% of HilleVax shares are owned by institutional investors. 12.7% of Annexon shares are owned by insiders. Comparatively, 71.1% of HilleVax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Annexon presently has a consensus price target of $15.80, indicating a potential upside of 462.28%. HilleVax has a consensus price target of $3.00, indicating a potential upside of 63.49%. Given Annexon's stronger consensus rating and higher possible upside, research analysts clearly believe Annexon is more favorable than HilleVax.
Annexon is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
Annexon received 44 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 77.14% of users gave Annexon an outperform vote while only 58.82% of users gave HilleVax an outperform vote.
Summary
Annexon beats HilleVax on 11 of the 15 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
This page (NASDAQ:HLVX) was last updated on 2/22/2025 by MarketBeat.com Staff
